Propanc Biopharma (PPCB) Income from Non-Controlling Interests (2010 - 2014)
Propanc Biopharma (PPCB) posted quarterly Income from Non-Controlling Interests of -$47909.0 for Q1 2014, down 1766.34% year-over-year from $2875.1 in Q1 2013, and down 185.4% quarter-over-quarter from $56099.0 in Q4 2013.
Propanc Biopharma (PPCB) Income from Non-Controlling Interests (2010 - 2014) Analysis & Trends
Propanc Biopharma (PPCB) has reported Income from Non-Controlling Interests for 5 consecutive years, with -$47909.0 the latest figure, recorded in Q1 2014.
- In Q1 2014, Income from Non-Controlling Interests fell 1766.34% year-over-year to -$47909.0; the TTM figure through Mar 2014 stood at $94267.0 (up 245.92% YoY), while the FY2013 annual figure was $114328.0, up 147.89% from the prior year.
- Income from Non-Controlling Interests fell to -$47909.0 in Q1 2014 per PPCB's latest filing, from $56099.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $252456.0 in Q4 2011 and bottomed at -$587026.0 in Q3 2011.
- Historically, Income from Non-Controlling Interests has averaged -$16354.0 across 5 years, with a median of -$4309.0 in 2011.
- Annual changes were most pronounced in 2013 — Income from Non-Controlling Interests soared 29166.84% — and 2014, when it plunged 1766.34%.
- Propanc Biopharma's Income from Non-Controlling Interests stood at $23262.0 in 2010, then jumped by 985.27% to $252456.0 in 2011, then tumbled by 100.08% to -$193.0 in 2012, then jumped by 29166.84% to $56099.0 in 2013, then plunged by 185.4% to -$47909.0 in 2014.
- Business Quant data shows PPCB's Income from Non-Controlling Interests at -$47909.0 in Q1 2014, $56099.0 in Q4 2013, and -$40931.0 in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | -47,909.00 |
| Dec 31, 2013 | 56,099.00 |
| Sep 30, 2013 | -40,931.00 |
| Jun 30, 2013 | 127,008.00 |
| Mar 31, 2013 | -2,567.00 |
| Dec 31, 2012 | -193.00 |
| Sep 30, 2012 | -9,920.00 |
| Jun 30, 2012 | -51,920.00 |
| Mar 31, 2012 | 147,758.00 |
| Dec 31, 2011 | 252,456.00 |
| Sep 30, 2011 | -587,026.00 |
| Jun 30, 2011 | -89,022.00 |
| Mar 31, 2011 | -6,051.00 |
| Dec 31, 2010 | 23,262.00 |